logo
A search continues for 6 people missing after a chemical plant explosion in China

A search continues for 6 people missing after a chemical plant explosion in China

CTV News5 days ago

Firefighters extinguish fires at the explosion site of a chemical plant in Gaomi, in east China's Shandong Province, Tuesday, May 27, 2025. (Xinhua via AP)
BEIJING — Rescuers searched Wednesday for six people still missing after an explosion at a chemical plant in eastern China shook nearby buildings, killing at least five people and injuring 19.
It was not immediately clear what caused the blast at an industrial park in the Shandong province city of Weifang. The explosion knocked out windows of nearby buildings and spewed a thick plume of white smoke, according to videos shared on social media.
Nearby residents on Wednesday were grappling with how or whether to rebuild damaged homes, while provincial authorities vowed to eliminate any further risks to ensure safety in manufacturing.
Zhang Liyou, who runs a restaurant about 1 kilometer away (less than a mile away) from the explosion site, was serving lunch when the blast occurred, shattering the restaurant's windows and causing part of its ceiling paneling to collapse.
Fortunately, neither him nor the handful of diners were harmed, he told The Associated Press, but the restaurant building, which also doubled as his home was covered with debris. He said he didn't know if he would reopen.
'There is no way for us to do the business anymore,' he said with a sigh.
The plant was separated from a nearby village by just a wheat field less than 700 meters (about a half mile) across. Residents told a state-backed media outlet, the Paper, that the blast had warped shutter doors, cracked walls and dislodged pieces of concrete from their roofs, and that they were worried about the structural integrity of their homes.
The plant is owned by Gaomi Youdao Chemical Co., a producer of pesticides and chemicals for medical use with more than 500 employees, according to corporate registration records.
Local fire officials sent more than 230 personnel to the scene, according to state broadcaster CCTV.
A student at a school about a kilometer away (less than a mile away) from the plant told the Paper that he heard an explosion and saw dirt-yellow smoke, tainted with redness, rising from the plant. He said there was a funny smell, and all students were given masks and told not to remove them.
It was unclear if there were any lingering health impacts after the initial explosion. A staffer at the local environment bureau told The Paper that a team was dispatched to the scene to monitor potential pollution but had yet to report back.
The blast came less than two weeks after the National Ministry of Emergency Management held a workshop on preventing and controlling risks in the chemical industry, as Beijing urged officials at chemical industrial parks to boost their capabilities in 'managing hazardous chemicals.'
Last year, the chemical plant was cited for 'safety risks' at least twice, but in September it was praised by the Weifang Emergency Management Bureau for relying on party members to effectively manage workplace risks. Specifically, party members at Gaomi Youdao identified more than 800 safety hazards in the first eight months of 2024 and rectified all of them, the bureau said.
Workplace safety has improved over the years in China but remains a stubborn problem. The National Ministry of Emergency Management recorded 21,800 incidents and 19,600 deaths in 2024.
A warehouse complex storing large amounts of hazardous chemicals caught fire and exploded in Tianjin in 2015, leaving 173 dead or missing.
In 2019, 78 people were killed in a blast at a chemical plant in Yancheng in China's eastern coastal province of Jiangsu.
___
Associated Press journalist Simina Mistreanu in Taipei, Taiwan, and news researcher Shihuan Chen in Beijing contributed to this report.
The Associated Press

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Ascentage Pharma Releases Promising Clinical Data on Alrizomadlin Monotherapy and Combinations in Solid Tumors
Ascentage Pharma Releases Promising Clinical Data on Alrizomadlin Monotherapy and Combinations in Solid Tumors

Globe and Mail

time2 hours ago

  • Globe and Mail

Ascentage Pharma Releases Promising Clinical Data on Alrizomadlin Monotherapy and Combinations in Solid Tumors

ROCKVILLE, Md. and SUZHOU, China, June 02, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers, announced that it has released the latest clinical data from its Phase II study of the MDM2-p53 inhibitor alrizomadlin (APG-115) as a single agent or in combination with PD-1 inhibitor toripalimab in patients with advanced adenoid cystic carcinoma (ACC) or other solid tumors in a poster presentation at the 61 st American Society of Clinical Oncology (ASCO) Annual Meeting. Alrizomadlin is the first MDM2-p53 inhibitor to enter clinical development in China and a key investigational drug candidate in Ascentage Pharma's apoptosis-targeted pipeline with global first-in-class potential. The ASCO Annual Meeting showcases the most cutting-edge research in clinical oncology and state-of-the-art advanced cancer therapies and is the world's most influential and prominent scientific gathering of the clinical oncology community. Returning to the ASCO Annual Meeting for the eighth consecutive year, Ascentage Pharma has garnered growing interest from the global research community. This year, two studies of the Bcl-2 inhibitor lisaftoclax (APG-2575) and the MDM2-p53 inhibitor alrizomadlin, key drug candidates in the company's apoptosis-targeted pipeline, have been selected for presentations, including an oral presentation, at the ASCO Annual Meeting. These clinical data on alrizomadlin in ACC and other solid tumors demonstrated the antitumor activity of alrizomadlin monotherapy in patients with advanced ACC or malignant peripheral nerve sheath tumor (MPNST). Moreover, alrizomadlin in combination with toripalimab was well tolerated and showed therapeutic potential in MPNST, biliary-tract cancer (BTC), and liposarcoma (LPS). Prof. Ye Guo, MD, a Principal Investigator of the study from the Department of Medical Oncology, Shanghai East Hospital, noted, 'ACC is a rare cancer type that lacks effective treatment options, and the treatment with antiangiogenic tyrosine kinase inhibitors faces certain limitations and safety concerns. At ASCO 2025, our team presented data of alrizomadlin in patients with ACC that demonstrated an objective response rate (ORR) of 16.7% and a disease control rate (DCR) of 100%. These results suggest that the targeted inhibition of the MDM2-p53 pathway has antitumor activity in ACC; therefore, it can potentially offer a new treatment strategy to patients with ACC.' Prof. Ning Li, MD, a Principal Investigator of the study from the Chinese Academy of Medical Sciences Cancer Hospital, commented, 'Currently, there are limited treatment options for patients with sarcomas such as MPNST and LPS. In this study, alrizomadlin both as a monotherapy and in combination with a PD-1 therapy, showed favorable antitumor activity in MPNST. The clinical benefit was particularly notable in patients who received the combination regimen, with two patients with MPNST achieving long-term responses that lasted more than 60 and 96 weeks, respectively. Furthermore, alrizomadlin in combination with a PD-1 therapy also showed clinical activity in LPS. These results suggest that alrizomadlin monotherapy and combination regimens may bring clinical benefit to more patients with sarcoma.' Dr. Yifan Zhai, Chief Medical Officer of Ascentage Pharma, said, 'Alrizomadlin is an investigational drug with global first-in-class potential. The clinical data presented at this year's ASCO Annual Meeting demonstrated the therapeutic potential of alrizomadlin, both as a monotherapy and in combinations, in ACC and other solid tumors, and underscored the synergistic effects between alrizomadlin and immunotherapies, thus suggesting a promising therapeutic strategy for various solid tumors. We are focused on addressing unmet clinical needs in China and around the world, and intend to further accelerate our clinical programs to advance more novel treatment options for patients as soon as possible.' Highlights of this abstract selected for presentation at ASCO 2025 are as follows: A Phase 2 Study of Novel MDM2 Inhibitor Alrizomadlin (APG-115) With or Without Toripalimab in Patients with Advanced Adenoid Cystic Carcinoma (ACC) or Other Solid Tumors Abstract #: 6102 Format: Poster Presentation Session Title: Head and Neck Cancer Principal Authors: Ye Guo, MD, Department of Medical Oncology, Shanghai East Hospital, China; Ning Li, MD, Chinese Academy of Medical Sciences Cancer Hospital, China; Xing Zhang, MD, Melanoma and Sarcoma Medical Oncology Unit, Sun Yat-sen University Cancer Center, China; Meiyu Fang, MD, Department of Rare Cancer & Head and Neck Medical Oncology, Cancer Hospital of the University of Chinese Academy of Sciences, China; Shuhang Wang, MD, Chinese Academy of Medical Sciences Cancer Hospital, China, et al. Highlights: Alrizomadlin is a novel investigational oral MDM2 inhibitor that has shown a manageable safety profile with initial clinical activity in ACC. As of the data cutoff date of February 13, 2025, 57 patients with advanced ACC, malignant peripheral nerve sheath tumor (MPNST), liposarcoma (LPS), biliary-tract cancer (BTC), and other tumors were enrolled. Alrizomadlin monotherapy showed encouraging antitumor activity in patients with advanced ACC or MPNST. Alrizomadlin in combination with toripalimab was also well tolerated and demonstrated antitumor activity in patients with MPNST, BTC, and LPS. In the monotherapy arm, 17 patients were efficacy-evaluable. The ORR was 16.7%, and the DCR was 100% in 12 patients with ACC. The DCR was 80% in 5 patients with MPNST, 4 of whom achieved stable disease (SD). In 24 safety-evaluable patients, 33.3% reported grade 3 or higher treatment-related adverse events (TRAEs). Three patients (12.5%) experienced treatment-related serious adverse events (SAEs). One patient discontinued treatment because of TRAE. In the combination arm, 29 patients were efficacy-evaluable. The ORR was 16.7% and the DCR was 100% in 6 patients with BTC. The ORR was also 16.7% and the DCR was 66.7% in 6 patients with LPS. Two patients with MPNST had confirmed partial response (PR) with prolonged progression free survival (PFS) of 60 + weeks and 96 + weeks, respectively. In 27 safety-evaluable patients treated with alrizomadlin at the 150 mg dose level, 12 (44.4%) experienced grade 3 or higher TRAEs. Treatment-related SAEs were reported in 8 patients (29.6%). One patient discontinued treatment because of TRAE. * Alrizomadlin (APG-115) is an investigational compound and has not been approved by the US FDA. About Ascentage Pharma Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855) is a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers. The company has built a rich pipeline of innovative drug candidates that includes inhibitors targeting key proteins in the apoptotic pathway, such as Bcl-2 and MDM2-p53 and next-generation kinase inhibitors. The lead asset, olverembatinib, is the first third-generation BCR-ABL1 inhibitor approved in China for the treatment of patients with CML in chronic phase (CML-CP) with T315I mutations, CML in accelerated phase (CML-AP) with T315I mutations, and CML-CP that is resistant or intolerant to first and second-generation TKIs. It is covered by the China National Reimbursement Drug List (NRDL). The Company is currently conducting an FDA-cleared, global registrational Phase III trial, or POLARIS-2, of olverembatinib for CML, as well as global registrational Phase III trials for newly diagnosed Ph+ ALL patients and SDH-deficient GIST patients. The second lead asset, lisaftoclax, is a novel Bcl-2 inhibitor for the treatment of various hematological malignancies. The NDA for the treatment of relapsed and/or refractory CLL and SLL was accepted with Priority Review designation by China's National Medical Products Administration. The Company is currently conducting an FDA-cleared, global registrational Phase III trial, or GLORA, of lisaftoclax in combination with BTK inhibitors for patients with CLL/SLL previously treated with BTK inhibitors for more than 12 months with sub-optimal response, as well as global registrational Phase III trials for newly diagnosed CLL/SLL, AML and MDS patients. Leveraging its robust R&D capabilities, Ascentage Pharma has built a portfolio of global intellectual property rights and entered into global partnerships and other relationships with numerous leading biotechnology and pharmaceutical companies, such as Takeda, AstraZeneca, Merck, Pfizer and Innovent, in addition to research and development relationships with leading research institutions, such as Dana-Farber Cancer Institute, Mayo Clinic, National Cancer Institute and the University of Michigan. For more information, visit Forward-Looking Statements This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, contained in this press release may be forward-looking statements, including statements that express Ascentage Pharma's opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results of operations or financial condition. These forward-looking statements are subject to a number of risks and uncertainties as discussed in Ascentage Pharma's filings with the SEC, including those set forth in the sections titled 'Risk factors' and 'Special note regarding forward-looking statements and industry data' in its Registration Statement on Form F-1, as amended, filed with the SEC on January 21, 2025, and the Form 20-F filed with the SEC on April 16, 2025, the sections headed 'Forward-looking Statements' and 'Risk Factors' in the prospectus of the Company for its Hong Kong initial public offering dated October 16, 2019, and other filings with the SEC and/or The Stock Exchange of Hong Kong Limited we made or make from time to time that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. The forward-looking statements contained in this presentation do not constitute profit forecast by the Company's management. As a result of these factors, you should not rely on these forward-looking statements as predictions of future events. The forward-looking statements contained in this press release are based on Ascentage Pharma's current expectations and beliefs concerning future developments and their potential effects and speak only as of the date of such statements. Ascentage Pharma does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Contacts Investor Relations: Hogan Wan, Head of IR and Strategy Ascentage Pharma +86 512 85557777 Stephanie Carrington ICR Healthcare +1 (646) 277-1282 Media Relations: Sean Leous ICR Healthcare +1 (646) 866-4012

Group of P.E.I. firefighters to join the fight against wildfires in western Canada
Group of P.E.I. firefighters to join the fight against wildfires in western Canada

CBC

time2 hours ago

  • CBC

Group of P.E.I. firefighters to join the fight against wildfires in western Canada

Social Sharing A dozen P.E.I. firefighters have been deployed to help fight the wildfires disrupting communities in western Canada. Ten forest firefighters have been sent to Saskatchewan, where there were 18 active fires as of Monday afternoon, with eight listed as not contained. On the border with neighbouring Manitoba, a huge fire continues to threaten Flin Flon, a city of 5,000 people. In addition to the 10 firefighters sent to Saskatchewan, two people have been sent to Manitoba to work as safety officers. Mike Montigny is the manager of field services at the P.E.I. Forests, Fish and Wildlife Division. "Every province, territory and federal agencies — including Parks Canada and the Department of National Defence — we all have signed agreements for mutual aid, knowing full well that you can't build a program for situations like Saskatchewan or the western part of Canada are facing right now," he said. "Knowing that we can support each other when needed, they don't need to carry that permanent burden of the staffing, the training, the resourcing... We can share resources across this country." Wildfire evacuees scramble to find somewhere to stay 21 hours ago Duration 4:50 With thousands of people forced to evacuate their communities because of wildfires, the next challenge is finding somewhere to stay, with some being sent as far away as Niagara Falls, Ont. Meanwhile, the 150 fires across the Prairies show few signs of slowing down. Montigny said extreme fire emergencies happen only once in 15 to 20 years, though they seem to be more frequent in recent years. The province of Saskatchewan declared a state of emergency on Thursday. About 20 communities have been under evacuation orders, with thousands displaced from their homes, many of them evacuated from remote communities by air. Some of the firefighters sent out west have gone through the first year of the P.E.I. department's wildland fire program. "We were able to get four great students this year," Montigny said. "They're excellent and so far they've been learning lots, and they're going to be buttoned in with some very, very experienced firefighters." Montigny said there are a few things the province looks for in potential candidates for the training program: People who are "able to learn quickly, to be physically fit — because it's a physically demanding job — and to be able to deal with the mental side of wildland fire as well too." Good training experience Montigny said helping other provinces will continue to let P.E.I.'s firefighting strength grow. "That knowledge and experience comes back home to the Island," he said. "We're able to see, especially some of the younger employees, they get a confidence, they get some experience... you can't get that kind of training." That confidence boost isn't just for the trainees, he added.

Man dead, woman hurt following motorcycle crash in Preeceville
Man dead, woman hurt following motorcycle crash in Preeceville

CTV News

time2 hours ago

  • CTV News

Man dead, woman hurt following motorcycle crash in Preeceville

An RCMP detachment can be seen in this file photo. (David Prisciak/CTV News) A 47-year-old man is dead after the motorcycle he was driving rolled on Highway 49 in Preeceville, Sask. late Friday night. According to Canora RCMP, officers along with local fire and EMS responded to the scene of the crash where the man was then pronounced dead. RCMP added that a female passenger on the motorcycle was assessed at the scene by EMS for injuries described as non-life-threatening. The crash remains under investigation. Preeceville, Sask. is located about 280 kilometres northeast of Regina.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store